Rexahn Pharma (RNN) Announces its Phase 2a Combination Study of RX-3117 and Abraxane in First-line Metastatic Pancreatic Cancer Patients Advances to Second Stage
Tweet Send to a Friend
Rexahn Pharmaceuticals, Inc. (NYSE American: RNN), a clinical-stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment of cancer, advances ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
